格卡瑞韦/哌仑他韦8周或12周方案治疗无肝硬化基因2、4、5或6型丙型肝炎病毒感染患者的疗效
三项3期试验评估格卡瑞韦/哌仑他韦治疗无肝硬化基因2、4、5或6型丙型肝炎病毒感染。8周方案在基因2型患者中持续病毒学应答率(SVR12)为98%,在基因4、5或6型患者中为93%;12周方案分别为99.5%和99%。药物安全性与安慰剂相似,病毒学失败率低于1%。
要点
- 8周格卡瑞韦/哌仑他韦方案在无肝硬化基因2型患者中SVR12达98%(95%CI 94.1-99.3)。
- 8周方案在基因4、5或6型患者中SVR12为93%(95%CI 83.6-97.3),无病毒学失败。
- 12周方案SVR12在基因2型为99.5%(95%CI 98.5-100),基因4、5或6型为99%(95%CI 97.6-100)。
核心结论
- 在3项3期研究中,8周格卡瑞韦/哌仑他韦治疗使无肝硬化慢性丙型肝炎基因2、4、5或6型感染患者中至少93%获得SVR12,病毒学失败率低于1%。
- 该药物组合的安全性与12周格卡瑞韦/哌仑他韦治疗相当。
研究设计与样本
- 研究包含2项开放标签单臂研究(SURVEYOR-II第4部分和ENDURANCE-4)以及1项随机双盲安慰剂对照研究(ENDURANCE-2)。
- ENDURANCE-2研究将无肝硬化初治或经治基因2型丙型肝炎成年患者按2:1随机分配至每日一次口服格卡瑞韦/哌仑他韦300 mg/120 mg组(n=202)或安慰剂组(n=100),疗程12周。
- SURVEYOR-II第4部分和ENDURANCE-4研究中,无肝硬化初治或经治基因2、4、5或6型丙型肝炎成年患者接受每日一次口服格卡瑞韦/哌仑他韦,分别治疗8周(SURVEYOR-II,n=145)或12周(ENDURANCE-4,n=121)。
- 所有研究的主要终点为意向治疗人群的治疗结束后12周持续病毒学应答(SVR12)。
主要发现
- 接受8周格卡瑞韦/哌仑他韦治疗的患者中,基因2型感染者SVR12率为98%(95%CI 94.1-99.3),基因4、5或6型感染者SVR12率为93%(95%CI 83.6-97.3)。
- 接受12周格卡瑞韦/哌仑他韦治疗的患者中,基因2型感染者SVR12率为99.5%(95%CI 98.5-100),基因4、5或6型感染者SVR12率为99%(95%CI 97.6-100)。
- 基因4、5或6型感染患者中未发生病毒学失败。
- 接受格卡瑞韦/哌仑他韦治疗的患者不良事件频率和严重程度与安慰剂组相似。
关键数值与推荐
- 8周方案:基因2型SVR12 98%(95%CI 94.1-99.3);基因4、5或6型SVR12 93%(95%CI 83.6-97.3)。
- 12周方案:基因2型SVR12 99.5%(95%CI 98.5-100);基因4、5或6型SVR12 99%(95%CI 97.6-100)。
- 病毒学失败率低于1%。
临床怎么用
- 对于无肝硬化的慢性丙型肝炎基因2、4、5或6型感染患者,8周格卡瑞韦/哌仑他韦方案可获得至少93%的SVR12,病毒学失败率低于1%。
- 该药物组合的安全性与12周方案相当。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Hepatitis C virus (HCV) has high genotypic diversity and global distribution. Agents that are effective against all major HCV genotypes, with shorter treatment duration, are needed to reduce disease burden. Glecaprevir (an NS3/4A protease inhibitor) and pibrentasvir (an NS5A inhibitor) have a high barrier to resistance and synergistic antiviral activity. We evaluated the safety and efficacy of 8 and 12 weeks' treatment with glecaprevir/pibrentasvir in patients with HCV genotype 2, 4, 5, or 6 infection without cirrhosis in 3 separate phase 3 trials. METHODS: We performed 2 open label, single-arm studies (SURVEYOR-II, Part 4 and ENDURANCE-4) and a randomized, double-blind, placebo-controlled study (ENDURANCE-2). In the ENDURANCE-2 study, adult patients with untreated or previously treated HCV genotype 2 infection without cirrhosis were randomly assigned (2:1) to groups given once-daily oral glecaprevir/pibrentasvir (n = 202; 300 mg/120 mg) or placebo (n = 100) for 12 weeks. In the SURVEYOR-II, Part 4 and ENDURANCE-4 studies, adult patients with untreated or previously treated patients with HCV genotype 2, genotype 4, genotype 5, or genotype 6 infection, without cirrhosis, were given once-daily oral glecaprevir/pibrentasvir (n = 121 in ENDURANCE-4 and n = 145 in SURVEYOR-II) for 12 or 8 weeks, respectively. In all studies the primary endpoint was sustained virologic response at 12 weeks after treatment (SVR12) in the intention-to-treat population. RESULTS: Among patients receiving glecaprevir/pibrentasvir for 8 weeks, rates of SVR12 were 98% (95% CI, 94.1-99.3) in those infected with HCV genotype 2 and 93% (95% CI, 83.6-97.3) in those infected with HCV genotypes 4, 5, or 6. Among patients receiving glecaprevir/pibrentasvir for 12 weeks, rates of SVR12 were 99.5% (95% CI, 98.5-100) in those infected with HCV genotype 2 and 99% (95% CI, 97.6-100) in those infected with HCV genotype 4, 5, or 6. No virologic failures occurred in patients with HCV genotype 4, 5, or 6 infections. The frequency and severity of adverse events in patients receiving glecaprevir/pibrentasvir were similar to those of patients who received placebo. CONCLUSION: In 3 Phase 3 studies, 8 weeks' treatment with glecaprevir/pibrentasivr produced an SVR12 in at least 93% of patients with chronic HCV genotype 2, 4, 5, or 6 infection without cirrhosis, with virologic failure in less than 1%. The drug combination had a safety profile comparable to 12 week's treatment with glecaprevir/pibrentasvir. ClinicalTrials.gov numbers: NCT02640482 (ENDURANCE-2), NCT02636595 (ENDURANCE-4), and NCT02243293 (SURVEYOR-II).
引用
- Asselah T, Kowdley KV, Zadeikis N, et al. Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis. Clin Gastroenterol Hepatol. 2017. PMID: 28951228. doi:10.1016/j.cgh.2017.09.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。